Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortés, Gallardo Carlos, Seock‐Ah Im et al.|The Lancet|2020Cited by 1.8k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Harold J. Burstein, Binghe Xu, Giuseppe Curigliano et al.|Annals of Oncology|2021Cited by 799